V6M1 logo

Relief Therapeutics Holding MUN:V6M1 Stock Report

Last Price

€2.11

Market Cap

€21.0m

7D

0%

1Y

-80.5%

Updated

25 Feb, 2024

Data

Company Financials

Relief Therapeutics Holding SA

MUN:V6M1 Stock Report

Market Cap: €21.0m

V6M1 Stock Overview

A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. More details

V6M1 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Relief Therapeutics Holding SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Relief Therapeutics Holding
Historical stock prices
Current Share PriceCHF 2.11
52 Week HighCHF 10.78
52 Week LowCHF 2.11
Beta-14.36
1 Month Change0%
3 Month Change0%
1 Year Change-80.47%
3 Year Changen/a
5 Year Changen/a
Change since IPO-88.63%

Recent News & Updates

Recent updates

Shareholder Returns

V6M1DE BiotechsDE Market
7D0%-3.5%-2.0%
1Y-80.5%-14.7%6.9%

Return vs Industry: V6M1 underperformed the German Biotechs industry which returned -24.1% over the past year.

Return vs Market: V6M1 underperformed the German Market which returned 2.3% over the past year.

Price Volatility

Is V6M1's price volatile compared to industry and market?
V6M1 volatility
V6M1 Average Weekly Movementn/a
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: V6M1 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine V6M1's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201369Michelle Lockwww.relieftherapeutics.com

Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.

Relief Therapeutics Holding SA Fundamentals Summary

How do Relief Therapeutics Holding's earnings and revenue compare to its market cap?
V6M1 fundamental statistics
Market cap€21.04m
Earnings (TTM)-€84.73m
Revenue (TTM)€6.15m

3.4x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
V6M1 income statement (TTM)
RevenueCHF 5.86m
Cost of RevenueCHF 1.45m
Gross ProfitCHF 4.41m
Other ExpensesCHF 85.20m
Earnings-CHF 80.79m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.44
Gross Margin75.26%
Net Profit Margin-1,378.18%
Debt/Equity Ratio1.8%

How did V6M1 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/25 10:41
End of Day Share Price 2023/11/28 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Relief Therapeutics Holding SA is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexandre MüllerResearch Dynamics
Bob PoolerValuationLAB AG